Moffitt Cancer Center Researchers Identify Genetic Variants for Prostate Cancers
News Jun 24, 2013
It relies on understanding the genetic interaction between single nucleotide polymorphisms (SNPs). The goal is to better predict a prostate cancer’s aggressiveness to avoid unnecessary radical treatment.
Their study was published in the online journal PLOS ONE in April.
According to the authors, prostate cancer accounts for 20 percent of all cancers and 9 percent of cancer deaths. It is the most common cancer and was the second leading cause of cancer death in American men in 2012.
“For most prostate cancer patients, the disease progresses relatively slowly,” said study co-author Hui-Yi Lin, Ph.D., assistant member of the Chemical Biology and Molecular Medicine Program at Moffitt. “However, some cases grow aggressively and metastasize. It is often difficult to tell the difference between the two.”
The two treatment options for aggressive prostate cancer — radical surgery and radiation therapy — have negative side effects, such as incontinence and erectile dysfunction. It is why the authors believe there is an urgent need for biomarkers that can identify or predict aggressive types of prostate cancer.
Through examining combinations of genetic variants, or SNP-SNP interactions, the researchers have identified and validated several genetic changes that are related to prostate cancer aggressiveness. Their work also shows that the epithelial growth factor receptor may be the hub for these interactions because it is involved in the growth of blood vessels (angiogenesis), which in turn stimulates tumor growth.
“Our findings identified five SNP-SNP interactions in the angiogenesis genes associated with prostate cancer aggressiveness,” explained study co-author Jong Y. Park, Ph.D., associate member of Moffitt’s Cancer Epidemiology Program. “We successfully detected the genotype combinations that put patients at risk of aggressive prostate cancer and then explored the underlying biological associations among angiogenesis genes associated with aggressive prostate cancer.”
The researchers concluded that the gene network they constructed based on SNP-SNP interactions indicates there are novel relationships among critical genes involved in the angiogenesis pathway in prostate cancer.
“Our findings will help physicians identify patients with an aggressive type of prostate cancer and may lead to better personalized treatment in the future,” Park said.
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018